{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:29:56Z","timestamp":1791462596839,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08408-y","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:02:24Z","timestamp":1725580944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thromboprophylaxis in oesophageal cancer patients\u2014a study protocol for a randomised, controlled trial (TOP-RCT)"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-9486","authenticated-orcid":false,"given":"Tua","family":"Gyldenholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Katballe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Willy","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Decker","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"8408_CR1","unstructured":"Engholm G. Statistik om Spiser\u00f8rskr\u00e6ft: Kr\u00e6ftens Bek\u00e6mpelse; 2020. Available from: https:\/\/www.cancer.dk\/spiseroerskraeft-oesofaguscancer\/statistik-om-spiserorskraeft\/. Cited 2020 20.07."},{"key":"8408_CR2","unstructured":"Shulze S, Sengel\u00f8v L, \u00d8gard CG. Spiser\u00f8rskr\u00e6ft 2020. Available from: https:\/\/www.sundhed.dk\/sundhedsfaglig\/laegehaandbogen\/mavetarm\/tilstandeogsygdomme\/spiseroer\/spiseroerskraeft\/. Cited 2020 20.07."},{"issue":"2","key":"8408_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00595-021-02260-2","volume":"52","author":"NA Theochari","year":"2022","unstructured":"Theochari NA, Theochari CA, Kokkinidis DG, Kechagias A, Lyros O, Giannopoulos S, et al. Venous thromboembolism after esophagectomy for cancer: a systematic review of the literature to evaluate incidence, risk factors, and prophylaxis. Surg Today. 2022;52(2):171\u201381.","journal-title":"Surg Today"},{"issue":"4","key":"8408_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jamcollsurg.2013.12.039","volume":"218","author":"RM Van Haren","year":"2014","unstructured":"Van Haren RM, Valle EJ, Thorson CM, Guarch GA, Jouria JM, Andrews DM, et al. Long-term coagulation changes after resection of thoracoabdominal malignancies. J Am Coll Surg. 2014;218(4):846\u201354.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"8408_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458\u201364.","journal-title":"Arch Intern Med"},{"key":"8408_CR6","unstructured":"Rasmussen MS, Dorff MH, Holt MI, Grove EL, Hvas AM. Cancer og Ven\u00f8s Tromboembolisme: Dansk Selskab for H\u00e6mostase og Trombose; 2017. Available from: http:\/\/www.dsth.dk\/pdf\/catretningslinje_2017.pdf. Cited 2020 20.07."},{"key":"8408_CR7","doi-asserted-by":"crossref","unstructured":"Boshier PR, Ziff C, Adam ME, Fehervari M, Markar SR, Hanna GB. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31(4).","DOI":"10.1093\/dote\/dox134"},{"issue":"1","key":"8408_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00268-016-3730-8","volume":"41","author":"M Reeh","year":"2017","unstructured":"Reeh M, Ghadban T, Dedow J, Vettorazzi E, Uzunoglu FG, Nentwich M, et al. Allogenic blood transfusion is associated with poor perioperative and long-term outcome in esophageal cancer. World J Surg. 2017;41(1):208\u201315.","journal-title":"World J Surg"},{"key":"8408_CR9","doi-asserted-by":"crossref","unstructured":"Sakamoto T, Fujiogi M, Matsui H, Fushimi K, Yasunaga H. Comparing perioperative mortality and morbidity of minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a nationwide retrospective analysis. Ann Surg. 2019.","DOI":"10.1097\/SLA.0000000000003500"},{"key":"8408_CR10","unstructured":"Schmidt LM, Foli-Andersen NJ, Rasmussen HM, Wille-Jorgensen PA. Thrombo-prophylaxis in Danish surgical departments. Status 2005 and 25 years' development. Ugeskr Laeger. 2008;170(11):947\u201351."},{"issue":"1","key":"8408_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21037\/jtd.2017.01.38","volume":"9","author":"J Agzarian","year":"2017","unstructured":"Agzarian J, Linkins LA, Schneider L, Hanna WC, Finley CJ, Schieman C, et al. Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. J Thorac Dis. 2017;9(1):80\u20137.","journal-title":"J Thorac Dis"},{"issue":"25","key":"8408_CR12","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","volume":"27","author":"C Ay","year":"2009","unstructured":"Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8408_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1634\/theoncologist.2017-0530","volume":"23","author":"K Syrigos","year":"2018","unstructured":"Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT study. Oncologist. 2018;23(11):1372\u201381.","journal-title":"Oncologist"},{"issue":"7","key":"8408_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1055\/s-0041-1727116","volume":"47","author":"JB Larsen","year":"2021","unstructured":"Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost. 2021;47(7):759\u201374.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"8408_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1076029607309176","volume":"14","author":"S Ota","year":"2008","unstructured":"Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, et al. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost. 2008;14(3):279\u201385.","journal-title":"Clin Appl Thromb Hemost"},{"key":"8408_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.thromres.2019.12.018","volume":"186","author":"M Lundbech","year":"2020","unstructured":"Lundbech M, Krag AE, Christensen TD, Hvas AM. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. Thromb Res. 2020;186:80\u20135.","journal-title":"Thromb Res"},{"key":"8408_CR17","doi-asserted-by":"crossref","unstructured":"Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin generation markers as predictors of cancer-associated venous thromboembolism: a systematic review. Semin Thromb Hemost. 2023.","DOI":"10.1055\/s-0043-1775856"},{"issue":"2","key":"8408_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"M Marshall-Webb","year":"2017","unstructured":"Marshall-Webb M, Bright T, Price T, Thompson SK, Watson DI. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017;30(2):1\u20137.","journal-title":"Dis Esophagus"},{"key":"8408_CR19","doi-asserted-by":"crossref","unstructured":"Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev. 2014 (6):CD009447.","DOI":"10.1002\/14651858.CD009447.pub2"},{"issue":"7","key":"8408_CR20","first-page":"1158","volume":"7","author":"JQ Song","year":"2015","unstructured":"Song JQ, Xuan LZ, Wu W, Huang JF, Zhong M. Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial. J Thorac Dis. 2015;7(7):1158\u201364.","journal-title":"J Thorac Dis"},{"issue":"5","key":"8408_CR21","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.21873\/anticanres.13385","volume":"39","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Yamada A, Hirata S, Tanaka H, Sakuratani T, Matsuhashi N, et al. Efficacy and safety of enoxaparin for prophylaxis of postoperative venous thromboembolism after esophagectomy: a single-center prospective randomized controlled phase II study. Anticancer Res. 2019;39(5):2615\u201325.","journal-title":"Anticancer Res"},{"key":"8408_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","volume":"151","author":"AA Khorana","year":"2017","unstructured":"Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;151:89\u201395.","journal-title":"Thromb Res"},{"key":"8408_CR23","unstructured":"DanskL\u00e6gemiddelInformation. Fragmin 2021. Available from: https:\/\/pro.medicin.dk\/medicin\/praeparater\/1245."},{"issue":"Suppl 8","key":"8408_CR24","doi-asserted-by":"publisher","first-page":"S963","DOI":"10.21037\/jtd.2018.04.70","volume":"10","author":"Y Shargall","year":"2018","unstructured":"Shargall Y, Litle VR. European perspectives in Thoracic Surgery, the ESTS venous thromboembolism (VTE) working group. J Thorac Dis. 2018;10(Suppl 8):S963\u20138.","journal-title":"J Thorac Dis"},{"issue":"1 Suppl","key":"8408_CR25","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S-94S.","journal-title":"Chest"},{"key":"8408_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2018.07.009","volume":"169","author":"M Lundbech","year":"2018","unstructured":"Lundbech M, Krag AE, Hvas AM. Prevalence of venous thromboembolism following head and neck cancer surgery: a systematic review and meta-analysis. Thromb Res. 2018;169:30\u20134.","journal-title":"Thromb Res"},{"key":"8408_CR27","unstructured":"World Health Organization. Definitions 2021. Available from: https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/trainingcourses\/definitions.pdf."},{"issue":"10","key":"8408_CR28","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.21037\/jtd-23-462","volume":"15","author":"T Lading","year":"2023","unstructured":"Lading T, Kjaer D, Bendixen M, Petersen TI, Christensen TD, Katballe N. Safe and efficient 2-step implementation of totally minimally invasive esophagectomy. J Thorac Dis. 2023;15(10):5362\u201370.","journal-title":"J Thorac Dis"},{"key":"8408_CR29","unstructured":"Oesophago-Gastric Anastomosis Study Group on behalf of the West Midlands Research Collaborative. Postoperative outcomes in oesophagectomy with trainee involvement. BJS Open. 2021;5(6)."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08408-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:08:21Z","timestamp":1725581301000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08408-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8408"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08408-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3918466\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients give their oral and written informed consent before inclusion.The study has been approved by the Danish Medicines Agency, the regional Scientific Committee and the Danish Data Protection Agency. The project management group holds monthly meetings to review trial conduct; the trial steering group meets every 6\u00a0months or more often as required. The study does not have a data monitoring committee, as the intervention was considered low-risk. The associated Good Clinical Practice (GCP) unit perform quarterly on-site monitoring visits and have full access to all original patient documentation. The study adheres to the General Data Protection Regulation (GDPR) and the Data Protection Act.The study has EudraCT registration number 2021\u2013001315-24 and is registered at ClinicalTrials.gov (study identifier: NCT05067153).The study is monitored by the Good Clinical Practice (GCP) Unit and conducted in accordance with the Declaration of Helsinki and applicable local regulatory requirements. The protocol manuscript adheres to the Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) guidelines (Supplementary Material 1).There was no patient or public involvement in the study conceptualisation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The protocol does not contain any pilot data and references only previously published data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TDC has been on the speaker bureaus for AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche Diagnostics, Takeda, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb, Chiesi Pharma AB and GlaxoSmithKline and on Advisory Boards for Bayer and Merck Sharp & Dohme (MSD), AstraZeneca and Sanofi.Other authors: None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"591"}}